Stimulator of interferon genes (STING) activation exacerbates experimental colitis in mice
Gary R Martin, Charlene M Blomquist, Kimiora L Henare, Frank R Jirik, Gary R Martin, Charlene M Blomquist, Kimiora L Henare, Frank R Jirik
Abstract
Detection of cytoplasmic DNA by the host's innate immune system is essential for microbial and endogenous pathogen recognition. In mammalian cells, an important sensor is the stimulator of interferon genes (STING) protein, which upon activation by bacterially-derived cyclic dinucleotides (cDNs) or cytosolic dsDNA (dsDNA), triggers type I interferons and pro-inflammatory cytokine production. Given the abundance of bacterially-derived cDNs in the gut, we determined whether STING deletion, or stimulation, acts to modulate the severity of intestinal inflammation in the dextran sodium sulphate (DSS) model of colitis. DSS was administered to Tmem173gt (STING-mutant) mice and to wild-type mice co-treated with DSS and a STING agonist. Colitis severity was markedly reduced in the DSS-treated Tmem173gt mice and greatly exacerbated in wild-type mice co-treated with the STING agonist. STING expression levels were also assessed in colonic tissues, murine bone marrow derived macrophages (BMDMs), and human THP-1 cells. M1 and M2 polarized THP-1 and murine BMDMs were also stimulated with STING agonists and ligands to assess their responses. STING expression was increased in both murine and human M1 polarized macrophages and a STING agonist repolarized M2 macrophages towards an M1-like subtype. Our results suggest that STING is involved in the host's response to acutely-induced colitis.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Woodward JJ, Iavarone AT, Portnoy DA. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science. 2010;328:1703–1705. doi: 10.1126/science.1189801.
- Danilchanka O, Mekalanos JJ. Cyclic dinucleotides and the innate immune response. Cell. 2013;154:962–970. doi: 10.1016/j.cell.2013.08.014.
- Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786–791. doi: 10.1126/science.1232458.
- Wu J, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339:826–830. doi: 10.1126/science.1229963.
- Chandra D, et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res. 2014;2:901–910. doi: 10.1158/2326-6066.CIR-13-0123.
- Gao P, et al. Structure-function analysis of STING activation by c[G(2′,5′)pA(3′,5′)p] and targeting by antiviral DMXAA. Cell. 2013;154:748–762. doi: 10.1016/j.cell.2013.07.023.
- Xiao TS, Fitzgerald KA. The cGAS-STING pathway for DNA sensing. Mol Cell. 2013;51:135–139. doi: 10.1016/j.molcel.2013.07.004.
- Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461:788–792. doi: 10.1038/nature08476.
- Abe T, et al. STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell. 2013;50:5–15. doi: 10.1016/j.molcel.2013.01.039.
- Barber GN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014;35:88–93. doi: 10.1016/j.it.2013.10.010.
- Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2′3′-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014;9(e99988):1–14.
- Schoggins JW, et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature. 2014;505:691–695. doi: 10.1038/nature12862.
- Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013;14:19–26. doi: 10.1038/ni.2491.
- Zhu Q, et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol. 2014;193:4779–4782. doi: 10.4049/jimmunol.1402051.
- Ahn J, et al. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun. 2014;5:5166. doi: 10.1038/ncomms6166.
- Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455:674–678. doi: 10.1038/nature07317.
- Canesso MCC, et al. The cytosolic sensor STING is required for intestinal homeostasis and control of inflammation. Mucosal Immunol. 2018;11:820–834. doi: 10.1038/mi.2017.88.
- Ahn J, Son S, Oliveira SC, Barber GN. STING-Dependent Signaling Underlies IL-10 Controlled Inflammatory Colitis. Cell Rep. 2017;21:3873–3884. doi: 10.1016/j.celrep.2017.11.101.
- Heipertz EL, Harper J, Walker WE. STING and TRIF Contribute to Mouse Sepsis, Depending on Severity of the Disease Model. Shock. 2017;47:621–631. doi: 10.1097/SHK.0000000000000771.
- Zeng L, et al. ALK is a therapeutic target for lethal sepsis. Sci Transl Med. 2017;9(eaan5689):1–15.
- Hu Q, et al. STING-mediated intestinal barrier dysfunction contributes to lethal sepsis. EBioMedicine. 2019;41:497–508. doi: 10.1016/j.ebiom.2019.02.055.
- Petrasek J, et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc Natl Acad Sci USA. 2013;110:16544–16549. doi: 10.1073/pnas.1308331110.
- Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci USA. 2012;109:19386–19391. doi: 10.1073/pnas.1215006109.
- Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371:507–518. doi: 10.1056/NEJMoa1312625.
- Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344–1367. doi: 10.1016/0016-5085(95)90599-5.
- Conlon J, et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol. 2013;190:5216–5225. doi: 10.4049/jimmunol.1300097.
- Lo Sasso G, et al. SIRT2 deficiency modulates macrophage polarization and susceptibility to experimental colitis. PLoS One. 2014;9(e103573):1–12.
- Chang HH, et al. PTPN22 modulates macrophage polarization and susceptibility to dextran sulfate sodium-induced colitis. J Immunol. 2013;191:2134–2143. doi: 10.4049/jimmunol.1203363.
- Arranz A, et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci USA. 2012;109:9517–9522. doi: 10.1073/pnas.1119038109.
- Formentini L, et al. Mitochondrial ROS Production Protects the Intestine from Inflammation through Functional M2 Macrophage Polarization. Cell Rep. 2017;19:1202–1213. doi: 10.1016/j.celrep.2017.04.036.
- Nagakawa Y, et al. Over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. Am J Transplant. 2004;4:1949–1957. doi: 10.1111/j.1600-6143.2004.00621.x.
- Morohashi T, et al. Allograft inflammatory factor-1 regulates trinitrobenzene sulphonic acid-induced colitis. Immunology. 2003;110:112–119. doi: 10.1046/j.1365-2567.2003.01714.x.
- Roman ID, et al. Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. Biomarkers. 2017;22:133–144. doi: 10.1080/1354750X.2016.1252950.
- Yang ZF, et al. Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. Int Immunol. 2005;17:1391–1397. doi: 10.1093/intimm/dxh316.
- Nagahara H, et al. Allograft inflammatory factor-1 in the pathogenesis of bleomycin-induced acute lung injury. Biosci Trends. 2016;10:47–53. doi: 10.5582/bst.2016.01027.
- Hunter MM, et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology. 2010;138:1395–1405. doi: 10.1053/j.gastro.2009.12.041.
- Weisser SB, et al. SHIP-deficient, alternatively activated macrophages protect mice during DSS-induced colitis. J Leukoc Biol. 2011;90:483–492. doi: 10.1189/jlb.0311124.
- Abdul-Sater AA, et al. Cyclic-di-GMP and cyclic-di-AMP activate the NLRP3 inflammasome. EMBO Rep. 2013;14:900–906. doi: 10.1038/embor.2013.132.
- Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature. Ann Pharmacother. 2013;47:537–542. doi: 10.1345/aph.1R526.
- Sprenger R, Sagmeister M, Offner F. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut. 2005;54:438–439.
- Rodrigues S, et al. Case series: ulcerative colitis, multiple sclerosis, and interferon-beta 1a. Inflamm Bowel Dis. 2010;16:2001–2003. doi: 10.1002/ibd.21242.
- McFarland AP, et al. Localized delivery of interferon-beta by Lactobacillus exacerbates experimental colitis. PLoS One. 2011;6(e16967):1–14.
- Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell. 1994;77:391–400. doi: 10.1016/0092-8674(94)90154-6.
- Peng L, Oganesyan V, Wu H, Dall’Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7:428–439. doi: 10.1080/19420862.2015.1007810.
- Tschurtschenthaler M, et al. Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. Gut. 2014;63:1921–1931. doi: 10.1136/gutjnl-2013-305863.
- Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in detente. Science. 2006;312:879–882. doi: 10.1126/science.1125676.
- Seow, C.H., Benchimol, E.I., Griffiths, A.M. & Steinhart, A.H. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, CD006790 (2008).
- Xia T, Konno H, Ahn J, Barber GN. Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. Cell Rep. 2016;14:282–297. doi: 10.1016/j.celrep.2015.12.029.
- Hu Y, Martin J, Le Leu R, Young GP. The colonic response to genotoxic carcinogens in the rat: regulation by dietary fibre. Carcinogenesis. 2002;23:1131–1137. doi: 10.1093/carcin/23.7.1131.
- Kerr CA, et al. Genomic homeostasis is dysregulated in favour of apoptosis in the colonic epithelium of the azoxymethane treated rat. BMC Physiol. 2013;13:2. doi: 10.1186/1472-6793-13-2.
- Patel S, et al. The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele. J Immunol. 2017;198:776–787. doi: 10.4049/jimmunol.1601585.
- Yi G, et al. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One. 2013;8(e77846):1–16.
- Jin L, et al. Identification and characterization of a loss-of-function human MPYS variant. Genes Immun. 2011;12:263–269. doi: 10.1038/gene.2010.75.
- Patel S, Jin L. TMEM173 variants and potential importance to human biology and disease. Genes Immun. 2018;20:82–89. doi: 10.1038/s41435-018-0029-9.
- Haag SM, et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559:269–273. doi: 10.1038/s41586-018-0287-8.
- Mähler M, et al. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol. 1998;274:G544–551.
- Brant SR, Nguyen GC. Is there a gender difference in the prevalence of Crohn’s disease or ulcerative colitis? Inflamm Bowel Dis. 2008;14(Suppl 2):S2–3. doi: 10.1097/00054725-200810001-00002.
- Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999;149:916–924. doi: 10.1093/oxfordjournals.aje.a009735.
- Martin GR, Keenan CM, Sharkey KA, Jirik FR. Endogenous prion protein attenuates experimentally induced colitis. Am J Pathol. 2011;179:2290–2301. doi: 10.1016/j.ajpath.2011.07.025.
Source: PubMed